Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cidara Therapeutics (CDTX) Capital Expenditures: 2017-2024

Historic Capital Expenditures for Cidara Therapeutics (CDTX) over the last 7 years, with Sep 2024 value amounting to $23,000.

  • Cidara Therapeutics' Capital Expenditures fell 81.75% to $23,000 in Q3 2024 from the same period last year, while for Sep 2024 it was $307,000, marking a year-over-year decrease of 8.63%. This contributed to the annual value of $129,000 for FY2024, which is 74.46% down from last year.
  • Cidara Therapeutics' Capital Expenditures amounted to $23,000 in Q3 2024, which was down 72.29% from $83,000 recorded in Q2 2024.
  • In the past 5 years, Cidara Therapeutics' Capital Expenditures registered a high of $178,000 during Q4 2023, and its lowest value of $9,000 during Q3 2022.
  • In the last 3 years, Cidara Therapeutics' Capital Expenditures had a median value of $83,000 in 2024 and averaged $68,364.
  • In the last 5 years, Cidara Therapeutics' Capital Expenditures plummeted by 82.29% in 2021 and then surged by 1,877.78% in 2023.
  • Over the past 5 years, Cidara Therapeutics' Capital Expenditures (Quarterly) stood at $54,000 in 2020, then slumped by 77.78% to $37,000 in 2021, then plummeted by 75.68% to $9,000 in 2022, then soared by 1,877.78% to $178,000 in 2023, then crashed by 81.75% to $23,000 in 2024.
  • Its Capital Expenditures stands at $23,000 for Q3 2024, versus $83,000 for Q2 2024 and $23,000 for Q1 2024.